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Abstract
Background: Guidelines for the management of anaemia in patients with chronic kidney disease
(CKD) recommend a minimal haemoglobin (Hb) target of 11 g/dL. Recent surveys indicate that this
requirement is not met in many patients in Europe. In most studies, Hb is only assessed over a
short-term period. The aim of this study was to examine the control of anaemia over a continuous
long-term period in Switzerland.
Methods: A prospective multi-centre observational study was conducted in dialysed patients
treated with recombinant human epoetin (EPO) beta, over a one-year follow-up period, with
monthly assessments of anaemia parameters.
Results: Three hundred and fifty patients from 27 centres, representing 14% of the dialysis
population in Switzerland, were included. Mean Hb was 11.9 ± 1.0 g/dL, and remained stable over
time. Eighty-five % of the patients achieved mean Hb ≥ 11 g/dL. Mean EPO dose was 155 ± 118 IU/
kg/week, being delivered mostly by subcutaneous route (64–71%). Mean serum ferritin and
transferrin saturation were 435 ± 253 μg/L and 30 ± 11%, respectively. At month 12, adequate iron
stores were found in 72.5% of patients, whereas absolute and functional iron deficiencies were
observed in only 5.1% and 17.8%, respectively. Multivariate analysis showed that diabetes
unexpectedly influenced Hb towards higher levels (12.1 ± 0.9 g/dL; p = 0.02). One year survival was
significantly higher in patients with Hb ≥ 11 g/dL than in those with Hb <11 g/dL (19.7% vs 7.3%, p
= 0.006).
Conclusion: In comparison to European studies of reference, this survey shows a remarkable and
continuous control of anaemia in Swiss dialysis centres. These results were reached through
moderately high EPO doses, mostly given subcutaneously, and careful iron therapy management.
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Background
Effective anaemia control in dialysis patients is associated
with many benefits, including lower mortality, morbidity
and better quality of life [1-6]. Despite significant
improvement in the last few years, recent surveys, such as
the European Survey in Anaemia Management (ESAM)
2003 [7] and the Dialysis Outcomes and Practice Pattern
Study II (DOPPS II) [8], show that the minimal haemo-
globin (Hb) target of 11 g/dL, proposed by the European
Best Practice Guidelines (EBPG) [9] and the Kidney Dis-
ease Outcomes Quality Initiative (K/DOQI) [10], was not
achieved in many patients. In Switzerland, only few data
on the control of anaemia in dialysed patients is available.
In ESAM 1998 [11], Switzerland achieved mean Hb of
11.7 g/dL (mean Hb of all countries was 11.4 g/dL). In
ESAM 1998 and 2003, the proportion of patients above
the minimal target of Hb >11 g/dL in this country were
65.1 and 78.9%, respectively, leaving many patients
under the target. It is noteworthy that ESAM 2003 was
based on a 1 day assessment, whereas data from ESAM
1998 has been collected during a six-months follow-up
period. It is known that Hb is fluctuating during long term
observations in dialysed patients [12-14]. Thus, we feel it
would be meaningful to study: A) the quality of anaemia
control in dialysed patients in Switzerland; B) if the con-
trol of anaemia and its treatment parameters could be
maintained over a long period of time, C) if co-morbidi-
ties may modulate Hb level and EPO dose, and D) if anae-
mia management has improved when compared with
earlier assessments.
Methods
Study design and data collection
This study was designed as a prospective, non-rand-
omized, observational survey. Patients were recruited
from November 2002 to March 2004. For each patient,
the observation period lasted 12 months. A concise, four-
pages report form was used for collecting baseline demo-
graphic data, clinical and laboratory parameters, as well as
anaemia treatment modalities at study entry, and then
monthly. The follow-up was only interrupted in the event
of a death, a renal transplantation, or if the patient was
lost to follow-up. Details of the study design and data col-
lection are summarized in figure 1. The recruitment was
performed in 27 dialysis centres, on a voluntary basis.
There were 3 university-based centres, 17 regional-based
and 7 private dialysis centres. According to Swiss law, an
informed consent is not needed for this type of survey. No
change in therapeutic strategy was requested during the
observational period. Additionally, a questionnaire was
sent to the participating centres, asking for centre-specific
targets for anaemia treatment such as Hb, serum ferritin
and transferrin saturation (TSAT).
Three categories of iron status were defined: 1) absolute
iron deficiency (ferritin <100 μg/L); 2) functional iron
deficiency (ferritin ≥ 100 μg/L and TSAT <20%); and 3)
adequate iron status (ferritin ≥ 100 < 800 μg/L and TSAT
≥ 20%).
Selection of patients
The study population were adult patients undergoing
maintenance renal replacement therapy, by either haemo-
dialysis, haemodiafiltration or peritoneal dialysis. No
minimal time on dialysis was requested. Adequate iron
status (ferritin ≥ 200 μg/l and TSAT ≥ 20%) was recom-
mended but not mandatory to be enrolled for the study.
Inclusion criteria were: i) age of ≥ 18 years; ii) either epo-
etin (EPO) pre-treated (any type of EPO) or EPO-naive
patients with newly diagnosed renal anaemia; iii) patients
had to be exclusively on EPO beta during the course of the
study. Exclusion criteria were the following: unstable
angina pectoris, untreated uncontrolled hypertension,
haemoglobinopathy, haemolysis, gastrointestinal bleed-
ing, acute infection or unstable systemic inflammatory
disease, epilepsy, pregnancy, lactation, deficiency of vita-
min B12 (<200 ng/L), deficiency of acid folic (<2 μg/L),
planned surgery during the survey period (except fistula
surgery), known hypersensitivity to EPO beta.
Participating centres were asked to include as many
patients as possible, on a voluntary basis, meeting the
inclusion/exclusion criteria. Ten dialysis centres included
more than 80% of all their patients treated with epoetin
beta, and 15 centres in total included more than 60% of
their patients receiving epoetin beta, contributing to 71%
of the patients included in this survey.
Data analysis
Simple statistical analyses were performed in Excel 2002
and for more complex statistics the SAS statistical program
version 8.2 (SAS, Institute, Cary NC, USA) was used.
Standard descriptive statistics (mean, standard deviation,
confidence interval) were calculated for all variables
including Hb, EPO dose, serum ferritin and TSAT. Means
were calculated on an individual basis (per patient) for
each month and thereafter and thereafter the means of the
monthly data were used to calculate the one year average
mean value for example for hemoglobin. Categorical var-
iables were presented in absolute number and percentage
and were compared with the X2-test whereas continuous
variables with the Student's t-test or Wilcoxon two-sample
test, where appropriate. The ANOVA model was used for
the efficacy comparison of the different routes of admin-
istration. The Kaplan Meier analysis was taken to calculate
survival probabilities. In the patients whose follow-up
was interrupted, the data were collected and analysedBMC Nephrology 2008, 9:16 http://www.biomedcentral.com/1471-2369/9/16
Page 3 of 11
(page number not for citation purposes)
until the last observation. The reasons for the interruption
of follow-up were: death (33), transplantation [7],
unknown reason [1]. Rare intermediate missing values of
patients (Hb, body weight, EPO dose, administration fre-
quency, route of administration), who received at least
one survey medication, were replaced by using the last
observation carried forward method (LOCF).
Univariate analysis was performed for Hb and EPO dose
regarding concomitant diseases, diagnosis, age and gen-
der. A multivariate analysis was performed which
included the covariates with p < 0.05 in the univariate
analysis. All statistical tests were two-sided and the signif-
icance was proofed on a 0.05 p-level.
Results
Demographics and baseline characteristics
Three hundred and seventy patients from 27 dialysis cen-
tres were initially recruited. Twenty patients were
excluded, because of major surgery (n = 4), bleeding (n =
2), and missing data (n = 14). Three hundred and fifty
patients were finally analysed, representing 14% of the
total dialysis population of Switzerland. Patients charac-
teristics are shown in table 1. Causes of end stage renal
disease (ESRD) and co-morbidities are described in table
2 and 3, respectively. Hypertension, diabetes and ischae-
mic heart disease were the most common concomitant
pathologies; these findings are comparable to ESAM
2003, though in the latter, 20.2% of the patients suffered
of peripheral vascular disease, compared to only 4.6% in
our survey.
Longitudinal assessment of Hb, iron status and EPO dose
Month to month assessments of Hb, EPO dose and iron
status, over the one-year observation period, are summa-
rized graphically in figure 2. The overall mean Hb concen-
tration based on the means of per patient values was 11.9
± 1.0 g/dL, with a slight trend to increase over time,
although not significantly. Mean weekly EPO dose was
155 ± 118 IU/kg/week, with a greater trend to increase
from baseline to month 12 (but not significant). Mean
Study design Figure 1
Study design. This was a prospective, observational survey in selected patients lasting from December 2003 (for the first 
patients included) to March 2005 (for the last patients included). Each single patient was observed during 12 months. Demo-
graphic and medical parameters, as specified in the figure, were collected at baseline, and then on a monthly basis.
Visits 
Survey start
December 2003
Survey end
December 2004
Baseline
Baseline
Medical history,
Epoetin beta dose,
frequency, route of 
administration,
Laboratory data (Hb,
Ferritin, transferrin
saturation (TSAT)
Monthly reports (M1-
M12)
Weight
EPO dose, frequency, 
route of administration
Laboratory data (Hb, 
ferritin, TSAT), 
Concomitant anaemia 
therapy
Final report
Questionnaire
assessing targets
in the treatment 
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serum ferritin and TSAT were 435 ± 253 μg/L and 30 ±
11%, respectively, with no significant variations.
The overall distribution of mean Hb is shown in figure 3.
Eighty five % of the patients achieved mean Hb ≥ 11 g/dL
and 44% had mean Hb ≥ 12 g/dL. The relationship
between Hb and EPO dose was examined. The require-
ment of EPO for each section of mean Hb level is shown
in the figure. Mean weekly EPO dose was significantly
lower (p < 0.0001) in patients with mean Hb ≥ 11 g/dL
(137 ± 86 IU/kg/week; 95% CI: 127–146 IU/kg/week) as
compared to patients with mean Hb <11 g/dL (255 ± 194
IU/kg/week; 95% CI: 203–307 IU/kg/week). A significant
negative correlation was found between overall mean
EPO dose and mean Hb level (r = -0.21; p < 0.0001).
Effect of gender, age and co-morbidities
Mean Hb (calculated as described above in figure 3) in
males was significantly higher than in females (12.0 ± 0.1
versus 11.7 ± 1.0 g/dL, p = 0.01). Mean EPO dose was
lower in men (146 ± 112 IU/kg/week) than in women
(167 ± 124 IU/kg/week), but this difference was not sig-
nificant (p = 0.11).
The influence of age was not significant. However, mean
EPO dose tended to be higher in women younger than 50
years compared to women older than 50 (199 ± 153 ver-
sus 159 ± 116 IU/kg/week; p = 0.21).
The influence of co-morbidities and primary renal diag-
nosis on mean Hb and EPO dose is shown in figure 4.
Mean Hb was ≥ 11 g/dL in all subgroups, but varied
according to co-morbidities and specific renal diagnosis.
In multivariate analysis, diabetes was found to influence
Hb towards a higher level (p = 0.004) and EPO require-
ments towards lower doses (p = 0.0004). Glomerulone-
phritis as a primary renal diagnosis influenced EPO
towards a higher dose (p = 0.008), but not Hb.
EPO administration and dose
At baseline, 71.1% of the patients received EPO beta sub-
cutaneously. The proportion of intravenous administra-
tion tended to increase from 29 to 36% over time. A stable
proportion of 68 to 70% of patients were treated with a
once weekly regimen. Mean Hb was identical in the
patients treated by intravenous or subcutaneous route.
However, EPO dose was significantly lower in favour of
the subcutaneous administration (114 ± 14 versus 187 ±
25 IU/kg/week, p = 0.035). For an identical mean Hb of
11.9 g/dL, patients treated once a week required a signifi-
cantly lower EPO dose compared to patients treated 2 or
3 times per week (129 ± 103 versus 229 ± 105 IU/kg/week,
p < 0.0001). This result is not surprising and only reflects
Table 1: Patients characteristics at baseline
(n = 350 patients) Mean ± SD
Age (years) 63.9 ± 14.5
Range 18–91
Female (%) 145 (41.4)
Male (%) 205 (58.5)
Haemodialysis/Haemodiafiltration (%) 332 (94.9)
Peritoneal dialysis (%) 18 (5.1)
EPO pre-treated (%) 330 (94.3)
EPO naive (%) 20 (5.7)
Body weight (kg) 69.9 ± 15.3
Range 40–129
Haemoglobin (g/dL) 11.7 ± 1.4
Range 6.8–15.5
Serum ferritin (μg/L) 404 ± 293
TSAT (%) 31 ± 15
Table 2: Causes of end-stage renal disease
Primary Renal Diagnosis n (%)
Glomerulonephritis 78 (22.3)
Diabetic nephropathy 75 (21.3)
Hypertension/vascular nephropathy 74 (21.1)
Pyelonephritis/interstitial nephritis 61 (17.4)
Polycystic kidney disease 27 (7.7)
Unclear/Multifactorial 13 (3.7)
Miscellaneous causes 11 (3.1)
Malignancies 9 (2.6)
Missing 12 (3.4)
Patients could be recorded with more than one primary diagnosis.
Table 3: Co-morbidities
n%
Hypertension 213 60.9
Diabetes1 96 27.4
Coronary artery disease 88 25.1
Congestive heart failure 55 15.7
Other cardiac diseases2 17 4.9
Vascular diseases3 16 4.6
Cancer (ca)4 14 4.0
Metabolic disorders5 72 . 0
Hepatological disorders6 72 . 0
Chronic obstructive pulmonary disease (COPD) 5 1.4
Hyperparathyroidism 4 1.1
Others (nephrectomy/ciclosporine nephropathy) 3 0.9
Amyloidosis 1 0.2
1 Diabetes (overall): including reported as primary diagnosis (n = 75 
patients)
2 Aneurysms (2); Mitral insufficiency (3); Paroxysmal tachycardia (1); 
Pericarditis (1); Valvulopathy (1); Replacement of aortic valve (1) 
Ischemic cardiopathy (8)
3 Arteriosclerosis, arteriopathy, polyarteriovascular disease (12); 
Cerebrovascular disorder (3); bleeding(1);
4 Cancer: reported as concomitant diseases: prostate ca (2); ear-nose-
throat ca (1); stomach ca (1); others and unknown (10)
5Obesity(3); Hypercholesterolaemia (1); Thyroiditis (1); Gout (2)
6Liver transplantation (1); Liver cirrhosis (4); Pancreatitis (2)
Patients could be recorded under more than one co-morbidity.BMC Nephrology 2008, 9:16 http://www.biomedcentral.com/1471-2369/9/16
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Monthly variations Figure 2
Monthly variations: month to month variations of mean Hb and EPO dose (upper panel A) and iron status (ferritin and 
transferrin saturation, TSAT, lower panel B) over the one-year observation period.
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the way epoetin beta is prescribed by Swiss nephrologists:
low doses are generally given once a week, whereas higher
doses (>10'000 IU/week) are divided into 2 or 3 injec-
tions.
Fifteen patients (4.3%) were found to be resistant to epo-
etin beta, defined by EPO doses higher than 300 IU/kg/
week and Hb <11 g/dL. The co-morbidities of these
patients were the following: coronary artery disease [4],
heart failure [3], other cardiac diseases [1], diabetes[2],
cancer [2], hypertension [4], liver disorder [1], chronic
inflammation [1].
Iron administration, iron status and adjuvant treatment of 
anaemia
In addition to EPO therapy, 97% of the patients received
at baseline anti-anaemia adjuvant medication. Two hun-
dred and thirty-two (68%) patients received iron substitu-
tion, intravenously (n = 187), orally (n = 21) or not
specified (n = 24). About 13% of the patients received
vitamins (including vitamin B12, vitamin C and folic
acid). Transfusions were required in 8 (2.2%) patients.
Ninety-two, 91 and 92% of the patients had serum ferritin
of ≥ 100 μg/L at baseline, month 6 and month 12, respec-
tively. The percentage of patients with absolute iron defi-
ciency ranged from 5.1 to 9.7% at any time during the
observation period. At month 12, adequate iron status
was found in 72.5% and functional iron deficiency in
17.8% of patients. The upper recommended limit of 800
μg/L was exceeded in 7.1% of the patients in this survey,
ranging from 5.7 to 11.1% over the 12-months observa-
tion period. Sixty % of our patients were within the opti-
mal ferritin target (200–500 μg/L) recommended by the
EBPG.
Mean EPO dose and mean Hb level with respect to iron
status are shown in figure 5. Overall, patients with "ade-
Mean Hb distribution over the follow-up period Figure 3
Mean Hb distribution over the follow-up period. Mean hemoglobin and EPO doses were first calculated on a per patient 
basis monthly and then over one year. Finally, the mean was calculated for the entire population with one mean per patient. 
The same was done for the EPO doses. Then, 5 Hb subgroups have been defined, according to sections of 1 g/dL.
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quate iron status" had the highest Hb with the lowest EPO
dose. At month 6 and 12, patients with "absolute iron
deficiency" increased their Hb (p = 0.0004 at month 6,
and 0.03 at month 12) compared to baseline values.
These patients also needed less EPO (p = 0.008 at month
6 and p = ns at month 12, vs at baseline). The group "func-
tional iron deficiency" had the lowest Hb level at month
6 and 12, despite the use of the highest EPO dose (>200
IU/kg/week).
Analysis of mortality: effect of Hb and EPO dose
Thirty-three patients (9.4%) died during the follow-up.
Patients with mean Hb ≥ 11 g/dL at baseline had a signif-
icantly better survival compared to patients with mean Hb
< 11 g/dL (mortality rate: 7.3% vs 19.7%, respectively; p =
0.006). Patients with mean Hb ≥ 12 g/dL at baseline
showed a mortality rate of 7% at one year, whereas those
with mean Hb < 12 g/dL had a mortality rate of 11.5%,
but this difference did not reach statistical significance.
As seen in figure 4, Hb was partially determined by co-
morbidities, which represents a non modifiable factor for
physicians. As Hb level was associated with mortality, we
questioned whether EPO dose, a physician-dependent
component of anaemia control, was associated with mor-
tality, regardless of Hb. Patients were stratified into 4 cat-
egories: Patients with Hb ≥ 11 g/dL and EPO dose ≥ 200
IU/kg/week; patients with Hb ≥ 11 g/dL and EPO dose <
200 IU/kg/week; patients with Hb < 11 g/dL and EPO
dose ≥ 200 IU/kg/week; and patients with Hb < 11 g/dL
and EPO dose < 200 IU/kg/week. Survival rates were ana-
lysed according to these categories. Survival rate was in
favour of patients with EPO doses lower than 200 IU/kg/
week and Hb greater than 11 g/dL, but this observation
Hb and EPO dose, according to co-morbidities and/or primary renal diagnosis Figure 4
Hb and EPO dose, according to co-morbidities and/or primary renal diagnosis. The mean ± SD of Hb and EPO 
doses as calculated in figure 3 are shown according to comorbidities or the primary renal diagnosis. Diabetes: n = 96; pyelone-
phritis/interstitial nephritis (PN/IN): n = 61; glomerulonephritis (GN): n = 78; coronary artery disease (CAD): n = 88; conges-
tive heart failure (HF): n = 55; cancer (ca): n = 14 (prostate ca (n = 2), ear-nose-throat ca (n = 1), stomach ca (n = 1), others ca 
non specified (n = 10); chronic obstructive pulmonary disease (COPD): n = 5. 1p = 0.004; 2p = 0.003; 3p = 0.008.
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failed to reach statistical significance (log rank test: p =
0.2). The same analysis was performed at a cut-off EPO
dose of 300 IU/kg/week, showing a nearly significant
lower survival probability in patients with lower Hb levels
(<11 g/dL) and EPO dose >300 IU/kg/week (log-rank test:
p = 0.064).
Centre-specific target for Hb and iron status
In order to understand how this optimal anaemia control
was achieved, nephrologists involved in the survey were
asked about their personal anaemia management prac-
tice, by means of a questionnaire. For Hb, all centres
aimed a target above 11 g/dL, with a range from 11 to 13.5
g/dL. In 15 of 27 centres (55.5%), target Hb was >12 g/dL.
Regarding serum ferritin, 26 centres aimed values > 200
μg/L and 1 centre > 150 μg/L. However, 30% of the centres
did not define upper limits as proposed by the EBGP.
Fourteen centres (51.8%) aimed a target range from 200
to 500 μg/L as recommended by the EBPG. For TSAT, 18
centres indicated a target range from 20 to 40%.
Discussion
With respect to ESAM 1998 [11], ESAM 2003 [7] and
DOPPS II [8], this survey demonstrates an optimal anae-
mia control, obtained in 85% of patients in a cohort of
dialysed patients in Switzerland followed prospectively
for 12 months. Mean Hb of 11.9 g/dL was remarkably sta-
ble throughout the whole observation period.
ESAM 1998 [11] found an overall mean Hb value of 11.4
g/dL with only 49% of the patients reaching the target
level. In ESAM 2003 [7], mean Hb levels were higher than
in 1998 (mean Hb of 11.5 g/dL with 66.1% of patients
having Hb>11 g/dL) in all but two countries. Recent data
from the DOPPS II study [8] shows a mean Hb concentra-
tion ranging from 10.1 g/dL in Japan to 12.0 g/dL in Swe-
Influence of iron status on Hb and EPO dose Figure 5
Influence of iron status on Hb and EPO dose. The iron status was divided into 3 categories, according to ferritin and 
TSAT (as defined in the text). Values at baseline, month 6 and 12 are shown. * Significant difference observed between patients 
with "adequate iron status" and "absolute iron deficiency" at baseline. ** Significant difference observed between patients with 
"functional iron deficiency" and "adequate iron stores" at month 6 (p = 0.0004 for Hb and p = 0.008 for the EPO dose) and 
month 12 (p = 0.03 for Hb, difference not significant for EPO dose).
*
*
0
50
100
150
200
250
Baseline Month 6 Month 12
E
p
o
 
d
o
s
e
 
(
I
U
/
k
g
/
w
e
e
k
)
8
9
10
11
12
13
14
M
e
a
n
 
H
b
(
g
/
d
L
)
Adequate iron 
status
Functional iron 
deficiency
Absolute iron 
deficiency
*
** **BMC Nephrology 2008, 9:16 http://www.biomedcentral.com/1471-2369/9/16
Page 9 of 11
(page number not for citation purposes)
den, but with important percentages of patients not
meeting the recommended target, even for countries with
the highest mean Hb (Sweden: mean Hb 12.0 g/dL, 23%
of the patients with Hb<11.g/dL; United States: mean Hb
11.7 g/dL, 27% of patients with Hb<11 g/dL; Spain: mean
Hb 11.7 g/dL, 31% of patients with Hb<11 g/dL).
In both ESAM studies Switzerland showed a better Hb
control compared to other countries. Looking at previous
assessments in Switzerland, the current survey suggests an
additional improvement from earlier studies regarding
both Hb (mean Hb of 11.7 g/dL in ESAM 1998 and 11.9
g/dL in the current study) and the percentage of patients
with Hb > 11 g/dL (65.1%, 78.9% and 85% in ESAM
1998, ESAM 2003 and the current study, respectively). It
must be stated however that the differences in the nature
and design in these studies require cautious interpretation
regarding such an improvement. Nonetheless, the current
results indicate that Swiss nephrologists have fully inte-
grated EBGP recommendations published in 1999 [11].
The revised version of these guidelines (2004) [9] which
proposes to tailor Hb from 11 to 14 g/dL according to co-
morbidities, age and other factors, was released during the
course of the present survey. It is unlikely to have influ-
enced Hb management in this study. Another Swiss trial,
prompted in 2005, is currently examining the impact of
the revised EBPG on physician's practice.
Several factors appear to have contributed to these good
results: first, our study shows a moderately high mean
EPO beta dose, slightly above the upper limit of EBPG rec-
ommendations (50–150 IU/kg/week), with a trend to
increase over the 12-months observation period. It is dif-
ficult to compare EPO doses between studies focussing on
anaemia management, because in ESAM 2003 [7] and
DOPPS II [8], EPO doses were not normalized to body
weight. Nevertheless, with reference to the mean body
weight of our patients, we calculated that mean EPO beta
dose was 10'835 IU/week, which was higher than mean
EPO used in ESAM 2003 (8'565 IU/week), but compara-
ble to mean EPO doses from 12 countries in DOPPS II
(ranging from 5'297 IU/week in Japan to 17'360 IU/week
in the US). ESAM 2003 already showed increased mean
EPO doses compared to ESAM 1998 [11] in all participat-
ing countries, certainly explaining most of the improve-
ment of anaemia control.
Second, the majority (70%) of our patients received EPO
subcutaneously compared to only 22.5% of the patients
in ESAM 2003. Even though mean Hb was comparable in
both ways of administration in our study, mean EPO dose
was significantly lower for subcutaneous than intravenous
administration. This finding confirms the better efficacy
of the subcutaneous administration of EPO beta. DOPPS
II [8] also reported an EPO dose reduction of about 14%
with subcutaneous administration, though a difference of
only 3% was reported in the US. ESAM 2003 showed that
the differences in EPO doses between subcutaneous and
intravenous administration were minimal for Hb values
>11 g/dL. However, for the intravenous group, EPO doses
were substantially higher for lower Hb values. It is thus
conceivable that the major subcutaneous use of EPO in
our study may has contributed to the current results.
Third, an adequate iron status is a crucial factor for achiev-
ing a satisfactory response to EPO therapy. Almost 73% of
our patients had an adequate iron status. Only a small
proportion of the patients (< 10%) had absolute iron defi-
ciency and only 17.8% of patients had functional iron
deficiency. Less than 10% had excessive iron stores. In the
DOPPS study [8], a larger proportion of patients (35–
40%) had TSAT < 20%, even though most of them were
administered intravenous iron. In ESAM 2003, only 48%
of the patients had adequate iron status and 31% had
TSAT values below 20% [7]. In order to understand how
nephrologists involved in our study managed iron defi-
ciency, we analysed whether the patients with absolute
and functional iron deficiency at baseline were corrected
during the follow-up. During the whole observation,
mean Hb level was lower and EPO dose higher in patients
with "absolute iron deficiency" compared to the group
with "adequate iron status". However, mean Hb of the
group "absolute iron deficiency" increased from baseline
to month 6 and 12, in parallel to a decrease of EPO
requirements, suggesting that physicians attempted to
correct for iron deficit. Thus, the management of iron
appeared to be adequate. In contrast, we did not observe
any Hb improvement over time in patients with" func-
tional iron deficiency", despite increased use of EPO: this
group had overall the lowest Hb (except at baseline,
month 3, 4 and 8) together with the highest dose of EPO
(except at baseline). As already shown in ESAM 1998 [11]
and 2003 [7], functional iron deficiency has a stronger
negative impact on Hb response rates than absolute iron
deficiency. This observation justifies special attention on
functional iron deficiency in the future, especially with
respect to the role of adjuvant therapy such as vitamin C
and carnitin. Finally, the questionnaire analysis shows
that Swiss nephrologists generally refer to EBPG, even if
the Hb target has been higher than recommended for
about half of the physicians involved. This strategy may
have driven some difficult patients towards a better con-
trol.
In order to identify factors potentially affecting anaemia
management, we assessed the effect of age, gender, etiolo-
gies of end stage renal disease (ESRD) and co-morbidities
on Hb level and EPO dose. Gender had a significant
impact on Hb, but not on EPO dose. However, we
observed a tendency for females to benefit from higherBMC Nephrology 2008, 9:16 http://www.biomedcentral.com/1471-2369/9/16
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EPO doses, suggesting a fair attempt by nephrologists to
equalize Hb between males and females. There was no
obvious effect of age. However, younger age (<50 years) in
women tended to influence Hb towards lower levels and,
as a possible physician's response, towards higher EPO
doses. In addition, older men (>60 years) tended to have
lower Hb than younger men. In ESAM 2003 [7], women
also had slightly lower mean Hb concentration than men,
without differences in EPO dose after adjustment for Hb
levels. Age had little effect on Hb and EPO dose, except for
patients aged 70–79 years. In the latter group, Hb
response rate and mean EPO dose were actually below
average. In comparison, DOPPS II [8] showed signifi-
cantly greater Hb for men, specially for the age group >75
years.
Etiologies of ESRD and co-morbidities were demonstrated
to determine anaemia control in this study. Diabetes (as a
primary renal diagnosis and concomitant disease) was
found to influence Hb to higher values and EPO delivery
to a lower dose. Glomerulonephritis influenced EPO to a
higher dose, but not Hb. Theses findings were unexpected.
ESAM 2003 showed that patients with diabetes were less
likely to achieve Hb ≥ 11 g/dL than those with other pri-
mary renal diagnosis and concomitant diseases. The rea-
son why diabetic patients have a higher Hb in our study is
not fully explained. However, in our study, patients with
diabetes had a significantly higher body weight than non
diabetic patients (78.0 ± 15.3 vs 68.0 ± 9.4 kg; p <
0.0001). A higher fat mass may stimulate erythropoiesis
through increased endogenous erythropoietin synthesis
and/or sensitivity via the adipocyte hormone leptin
[15,16]. We indeed observed a significant positive correla-
tion between body weight and Hb (p: 0.0255, r = 0.115).
It is thus speculated that the higher fat mass in our dia-
betic patients might be responsible for their increased Hb.
Patients with Hb>11 g/dL had a significantly better sur-
vival compared to patients with Hb<11 g/dL. A trend
towards improved survival was also observed with an Hb
cut-off of 12 g/dL. We also assessed the influence of EPO
dose on mortality and found a trend for a lower mortality
in patients with Hb>11 g/dL and EPO dose <200 IU/kg/
week, compared to the same Hb level but EPO dose ≥ 200
IU/kg/week. These results are consistent with those in
DOPPS II, showing a mortality risk to be 5% lower for
every increase of 1 g/dL in Hb concentration. Our data are
also in line with the large analysis of Ofsthun et al [17],
which showed a mortality benefit for patients beyond the
current recommended Hb target. However, we are aware
that observational data, such as those presented in this
study, is not sufficient to determine the optimal Hb target.
Indeed, prospective randomized controlled trials showed
that complete normalization of Hb from 126 to 135 g/dL
has adverse effects on mortality and morbidity parameters
such as blood pressure control in chronic kidney disease
stages 3 and 4 [18,19], and on arterio-venous access
thrombosis and mortality in dialysis patients [20]. In con-
trast, quality of life is improved when Hb is normalised
[18]. Thus, a long-standing controversy still exists, espe-
cially with regard to the upper limit of Hb concentration
to suggest [21]. The Hb target aimed by Swiss nephrolo-
gists in the current study ranged from 11 to 13,5 g/dL,
probably reflecting this controversy.
This survey has several limitations: First, although repre-
senting 14% of the Swiss dialysis population, it includes a
relatively small number of patients, which limits its statis-
tical power. Second, we did not look at several parameters
known to influence Hb level and EPO dose, such as resid-
ual renal function, adequacy parameters, inflammation/
infection, nutritional parameters, treatment with ACE
inhibitors, angiotensin II receptor antagonists and level of
iPTH. Third, this is an observational study and even
though we paid special attention in order to avoid selec-
tion bias, this can't be formally excluded, as there was no
random selection into the study. Although exclusion crite-
ria were respected, some unstable patients may have been
excluded. This might theoretically have affected our data
in a positive fashion. In contrast, some other factors may
have had a negative impact on the results: No minimal
time on dialysis was requested. It is known that new inci-
dent dialysis patients have a lower Hb. We have included
twenty EPO-naive patients, who, in general, had a lower
Hb than EPO pre-treated patients. Whether the inclusion
of these patients had an influence on mean Hb was not
tested. Nevertheless, in spite of the above limitations,
patients included in this study have similar characteris-
tics/co-morbidities compared to ESAM 2003 [7]. With
respect to the exclusion criteria, the only selection made
was the exclusive use of epoetin beta, as stated in the
inclusion criteria. Therefore, the hypothesis that a selec-
tion bias may have significantly affected our results in a
positive fashion appears unlikely.
Conclusion
In comparison to ESAM 2003 and DOPPS II, this survey
shows an optimal and sustained quality control of anae-
mia in a cohort of dialysis patients in Switzerland, fol-
lowed prospectively for 12 months. Such a control was
reached through doses of EPO beta in the upper range of
EBPG recommendations, preferential use of subcutane-
ous administration of EPO and careful management of
iron therapy.
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